These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16009523)

  • 1. An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.
    Nageswara Rao R; Meena S; Raghuram Rao A
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):349-63. PubMed ID: 16009523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 3. Are all COX-2 inhibitors created equal?
    Chang IJ; Harris RC
    Hypertension; 2005 Feb; 45(2):178-80. PubMed ID: 15623540
    [No Abstract]   [Full Text] [Related]  

  • 4. The new NSAIDs: cox-2 inhibitors.
    Capriotti T
    Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
    [No Abstract]   [Full Text] [Related]  

  • 5. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
    Rioda WT; Nervetti A
    Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
    Walter MF; Jacob RF; Day CA; Dahlborg R; Weng Y; Mason RP
    Atherosclerosis; 2004 Dec; 177(2):235-43. PubMed ID: 15530895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.
    Schwartz JI; Dallob AL; Larson PJ; Laterza OF; Miller J; Royalty J; Snyder KM; Chappell DL; Hilliard DA; Flynn ME; Cavanaugh PF; Wagner JA
    J Clin Pharmacol; 2008 Jun; 48(6):745-54. PubMed ID: 18434566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
    Kusunoki N; Yamazaki R; Kawai S
    Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
    J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
    Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.
    Ahuja N; Singh A; Singh B
    J Pharm Pharmacol; 2003 Jul; 55(7):859-94. PubMed ID: 12906745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new NSAID selective COX-2 inhibitor].
    Ledro Cano D; Gómez Rodríguez B; Torres Domínguez Y; Hergueta Delgado P; Herrerías Esteban J; Herrerías Gutiérrez J
    Rev Esp Enferm Dig; 1999 Aug; 91(8):598. PubMed ID: 10491496
    [No Abstract]   [Full Text] [Related]  

  • 15. Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
    Wang BH; Bertucci MC; Ma JY; Adrahtas A; Cheung RY; Krum H
    Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):912-8. PubMed ID: 20497423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension.
    Hermann M; Shaw S; Kiss E; Camici G; Bühler N; Chenevard R; Lüscher TF; Gröne HJ; Ruschitzka F
    Hypertension; 2005 Feb; 45(2):193-7. PubMed ID: 15630049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
    Zhu FS; Chen XM; Wang YJ; Zhang X; Feng JX
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):186-8. PubMed ID: 17649633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy?
    Romanovsky AA
    Am J Physiol Regul Integr Comp Physiol; 2005 May; 288(5):R1098-9. PubMed ID: 15821282
    [No Abstract]   [Full Text] [Related]  

  • 19. Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.
    Buecher B; Bouancheau D; Broquet A; Bezieau S; Denis MG; Bonnet C; Heymann MF; Jarry A; Galmiche JP; Blottière HM
    Anticancer Res; 2005; 25(1A):225-33. PubMed ID: 15816542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Aug; 95(2):154-8. PubMed ID: 16136765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.